Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure (HARPS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00585546 |
Recruitment Status
:
Terminated
(No longer could obtain clenbuterol)
First Posted
: January 3, 2008
Results First Posted
: December 15, 2017
Last Update Posted
: December 15, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Tracking Information | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | December 26, 2007 | |||||||||
First Posted Date ICMJE | January 3, 2008 | |||||||||
Results First Submitted Date | March 25, 2017 | |||||||||
Results First Posted Date | December 15, 2017 | |||||||||
Last Update Posted Date | December 15, 2017 | |||||||||
Study Start Date ICMJE | July 2007 | |||||||||
Actual Primary Completion Date | March 2010 (Final data collection date for primary outcome measure) | |||||||||
Current Primary Outcome Measures ICMJE |
Percent of Subjects Who Experience LVAD Removal and Subsequent Freedom From Mechanical Circulatory Support or Heart Transplantation for 1-year After Explantation [ Time Frame: One year after LVAD explant or until transplant or death (if not explanted) ] | |||||||||
Original Primary Outcome Measures ICMJE |
Percent of subjects who experience LVAD removal and subsequent freedom from mechanical circulatory support or heart transplantation for 1-year after explantation. [ Time Frame: One year after LVAD explant or until transplant or death (if not explanted) ] | |||||||||
Change History | Complete list of historical versions of study NCT00585546 on ClinicalTrials.gov Archive Site | |||||||||
Current Secondary Outcome Measures ICMJE |
|
|||||||||
Original Secondary Outcome Measures ICMJE |
|
|||||||||
Current Other Outcome Measures ICMJE | Not Provided | |||||||||
Original Other Outcome Measures ICMJE | Not Provided | |||||||||
Descriptive Information | ||||||||||
Brief Title ICMJE | Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure | |||||||||
Official Title ICMJE | Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol. | |||||||||
Brief Summary | The purpose of this study is to evaluate whether patients with chronic heart failure not due to coronary artery disease who require use of a left ventricular assist device (LVAD) for refractory heart failure can recover sufficient heart function to allow the pump to be explanted. The study aims to avoid the need for transplantation in these patients by using standard heart failure medications to reduce the size of the left ventricle and then using the investigational drug, clenbuterol, to further improve left ventricular function. | |||||||||
Detailed Description | The hypothesis of this study is that patients with dilated nonischemic cardiomyopathy who require support with an implanted left ventricular assist device (LVAD) for chronic refractory heart failure can, with a specific two-staged medical regimen designed to enhance maximal reverse remodeling (an angiotensin converting enzyme inhibitor, beta blocker, angiotensin receptor blocker, aldosterone antagonist and digoxin [stage 1]) and prevent/reverse myocardial atrophy (the β2 agonist clenbuterol [stage 2]), recover adequate left ventricular systolic function to allow LVAD explantation and subsequent intermediate-term survival without need for mechanical circulatory support or heart transplantation. Within one year of this study's start, a new LVAD became the standard of care for implantation, so the study device became an inferior standard of care shortly thereafter. By 2012 the trial was stopped for futility in enrollment. Thus, certain original outcomes have been deleted, specifically because there was only a single subject explanted, multivariate analysis for sustainability of reverse remodeling following LVAD explantation and predictors of recovery of left ventricular function/remodeling and of LVAD removal could not be done. Similarly, and for lack of funding, biobank components were not collected; therefore no data exists to present biochemical, structural, cellular and molecular changes in the myocardium resulting from the HARPS protocol interventions, changes in systemic inflammation, circulating progenitor cells and growth factors, or DEXA scan based data: changes in body mass, lean muscle mass, muscle strength and maximal and submaximal exercise capacity. All remaining outcome measures have been edited to more precisely show the outcome measures intended. |
|||||||||
Study Type ICMJE | Interventional | |||||||||
Study Phase | Phase 1 | |||||||||
Study Design ICMJE | Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
|||||||||
Condition ICMJE |
|
|||||||||
Intervention ICMJE | Drug: clenbuterol
Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.
Other Name: Spiropent |
|||||||||
Study Arms | Experimental: LVAD and Clenbuterol
Intervention: Drug: clenbuterol |
|||||||||
Publications * | Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M, Banner NR, Khaghani A, Yacoub MH. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006 Nov 2;355(18):1873-84. | |||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||||||||
Recruitment Information | ||||||||||
Recruitment Status ICMJE | Terminated | |||||||||
Actual Enrollment ICMJE |
18 | |||||||||
Original Estimated Enrollment ICMJE |
40 | |||||||||
Actual Study Completion Date | March 2010 | |||||||||
Actual Primary Completion Date | March 2010 (Final data collection date for primary outcome measure) | |||||||||
Eligibility Criteria ICMJE | Inclusion Criteria: Patients with refractory symptomatic heart failure (NYHA Class IV, or Stage D) due to dilated, non-ischemic cardiomyopathy who meet the following criteria:
Exclusion Criteria:
|
|||||||||
Sex/Gender |
|
|||||||||
Ages | 18 Years and older (Adult, Senior) | |||||||||
Accepts Healthy Volunteers | No | |||||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||||||||
Listed Location Countries ICMJE | United States | |||||||||
Removed Location Countries | ||||||||||
Administrative Information | ||||||||||
NCT Number ICMJE | NCT00585546 | |||||||||
Other Study ID Numbers ICMJE | HARPS | |||||||||
Has Data Monitoring Committee | Yes | |||||||||
U.S. FDA-regulated Product |
|
|||||||||
IPD Sharing Statement | Not Provided | |||||||||
Responsible Party | Francis D. Pagani, University of Michigan | |||||||||
Study Sponsor ICMJE | Francis D. Pagani | |||||||||
Collaborators ICMJE |
|
|||||||||
Investigators ICMJE |
|
|||||||||
PRS Account | University of Michigan | |||||||||
Verification Date | May 2017 | |||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |